Page 3 - Nppa

NPPA fines health hub for overcharging on stents

On February 13, NPPA had capped the price of drug-eluting stents at Rs 29,600

NPPA fixes ceiling price of 30 more formulations

Total number of formulations under the price control since April 2016 has reached around 760

NPPA finalises format to monitor price of 19 medical devices

Currently, the government monitors the price movement of 19 medical devices

NPPA revises rates of 6 drugs, fixes price of 1 medicine

It has fixed the price of P-PPi-L capsules which are used for treating acidity

No proposal to extend price cap to other medical devices, says NPPA chief

National Pharmaceutical Pricing Authority (NPPA) chairman Bhupendra Singh has said there was no proposal "as of now" to extend a price cap to other medical devices.The government has categorised 22 medical devices as drugs. Among these, four products, including cardiac stents, are categorised as scheduled drugs and NPPA can cap their price under law. In respect of other devices such as catheters, heart valves and intra ocular devices (categorised as non-scheduled drugs), the government allows for a 10 per cent price hike in a year.While the NPPA is monitoring the prices, fixing those for other devices is not on the agenda, Singh said on Thursday. He met representatives of pharmaceutical companies and hospitals in this city, to understand their concerns on drug pricing and particularly on capping of stent prices. Singh said all the stents being sold in India will continue to be available. On Wednesday, NPPA rejected requests from device makers Abbott Healthcare and Medtronic ..

NPPA fixes prices of 20 drugs, stents made costlier

Drug Eluting Stents will now be priced at Rs 30,180 and Bare Metal Stents at Rs 7,400

Medical devices notified as drug should carry MRP on packs: NPPA

The government has notified 22 medical devices as drugs under the Drugs and Cosmetics Act, 1940

NPPA's drug overcharging penalty at a record high

The regulator has registered 1,493 cases of overcharging since its inception in 1997

A few more drugs to come under price control: NPPA

The regulator has been fixing and revising the prices of drugs

NPPA heat on hospitals for failing to provide stent details

Hospitals not providing these details could be accused of distorting evidence deliberately

NPPA asks hospitals, stent makers to list prices on websites

NPPA also asked stent makers, marketers and importers to undertake similar exercise

Drug price regulator identifies 3 hospitals overcharging for stents

As the controversy on stent availability and pricing intensifies, the National Pharmaceutical Pricing Authority (NPPA) has now started to crack the whip on hospitals. The pharma pricing authority said that three hospitals have been identified to be overcharging based on complaints it received on its helpline. The NPPA is investigating these matters. Last week the pharma pricing authority ordered cap on prices for stents, which are used for treating narrow or weak arteries, last week. In a notification, it set the cap of Rs 7260 for bare metal stents and Rs 29,600 for drug eluting as well as well as biodegradable stents. As the NPPA has no jurisdiction to curb the price of ancillary products such as balloon-catheters and guide wires, its strategy is to ensure that that manufacturers and hospitals do not try to create an artificial shortage. The NPPA also cannot control procedure costs at hospitals."Hospitals must first raise demand to company before complaining of shortage," says ...

Expert panel recommends expanding NPPA's mandate

At present, the NPPA monitors drugs that are part of NLEM and identifies players that overcharge

Regulator should fix prices for drugs not in essential list too: Panel

At present, the NPPA monitors drugs which are part of the National List of Essential Medicines

Pharma price regulator asks manufacturers to submit stent pricing data within one week

The notification was issued on 5th October, 2016

NPPA approves norms for discontinuation of scheduled drugs

The body may also consider an upwards price revision if the drug is being discontinued because of non remunerative pricing

Grim diagnosis for pharma firms haunted by price bogey

DoP directs NPPA to dig up 37-year-old cases of overpriced drugs

NPPA to cap coronary stent prices

Will meet industry representatives this month for inputs on stent prices

NPPA caps prices of another 50 drugs

The agency is also planning to cap the prices of 40 other drugs.

NPPA examining 92 applications to fix price of new FDCs

Also, last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend